Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-7479d7b7d-fwgfc Total loading time: 0 Render date: 2024-07-08T12:50:34.798Z Has data issue: false hasContentIssue false

Chapter 20 - Management of multiple myeloma in older adults

from Part 3 - Management of hematologic malignancies in older adults

Published online by Cambridge University Press:  05 August 2011

By
Amrita Y. Krishnan
Edited by
Arti Hurria  and
Harvey Jay Cohen
Arti Hurria
Affiliation:
City of Hope Cancer Center, California
Harvey Jay Cohen
Affiliation:
Duke University Medical Center, Durham
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Practical Geriatric Oncology , pp. 288 - 296
Publisher: Cambridge University Press
Print publication year: 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Anagnostopoulos, A, Gika, D, Symeonidis, A. Multiple myeloma in elderly patients: prognostic factors and outcome. Eur J Haematol. 2005;75(5):370–375.CrossRefGoogle ScholarPubMed
Phekoo, KJ, Schey, SA, Richards, MA. A population study to define the incidence and survival of multiple myeloma in a national health service region in UK. Br J Haematol. 2004;127(3):299–304.CrossRefGoogle Scholar
Kyle, R, Therneau, T, Rajkumar, S. A long term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346(8):564–569.CrossRefGoogle ScholarPubMed
Witzig, TE, Kyle, RA, O'Fallon, W. Detection of peripheral blood plasma cells as a predictor of disease course in patients with smoldering myeloma. Br J Haematol. 1994;87(2):266–272.CrossRefGoogle Scholar
Greipp, PR, San Miguel, J, Durie, BG. International staging system for myeloma. J Clin Oncol. 2005;23(15):3412–3420.CrossRefGoogle ScholarPubMed
Ludwig, H, Durie, BG, Bolejack, V. Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10549 patients from the International Myeloma Working Group. Blood. 2008;111(8):4039–4047.CrossRefGoogle Scholar
Nilsson, T, Lenhoff, S, Turession, I. Cytogenetic features of multiple myeloma: impact of gender, age, disease phase, culture time and cytokine stimulation. Eur J Haematol. 2002;68(6):345–353.CrossRefGoogle ScholarPubMed
Sagaster, V, Kaufman, H, Odelga, V. Chromosomal abnormalities of young multiple myeloma patients are not different from those of other age groups and are independent of stage according to the International Staging System. Eur J Haematol. 2007;78(3):227–234.CrossRefGoogle Scholar
Alexanian, R, Haut, A, Khan, AU. Treatment for myeloma; combination chemotherapy with different melphalan dose regimens. J Am Med Assoc. 1969;208:1680–1685.CrossRefGoogle ScholarPubMed
Alexanian, R, Weber, D, Anagnostopoulos, A. Thalidomide with or without dexamethasone for refractory or relapsing myeloma. Semin Hematol. 2003;40(suppl 4):3–7.CrossRefGoogle ScholarPubMed
Singhal, S, Mehta, J, Desikan, R. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 2001;341(21):1565–1571.CrossRefGoogle Scholar
Rajkumar, SV, Rosinol, L, Hussein, M. Multicenter randomized double-blind placebo controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol. 2008;26:2171–2177.CrossRefGoogle ScholarPubMed
Ludwig, H, Hajek, R, Tothova, E. Thalidomide dexamethasone compared to melphalan prednisolone in elderly patients with multiple myeloma. Blood. 2008;113(5):3435–3442.CrossRefGoogle ScholarPubMed
Palumbo, A, Bringhen, S, Caravita, T. Oral melphalan and predinose chemotherapy plus thalidomide compared with melphalan and predisone alone in elderly patients with myeloma: randomised controlled trial. Lancet. 2006;367(9513):825–831.CrossRefGoogle Scholar
Facon, T, Mary, JY, Hulin, C. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced intensity autologous stem cell transplantation in elderly patients with multiple myeloma. Lancet. 2007;370(9594):1209–1218.CrossRefGoogle ScholarPubMed
Dimopoulos, M, Spencer, A, Attal, M. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. New Engl J Med. 2007;357(21):2123–2132.CrossRefGoogle ScholarPubMed
Weber, D, Chen, C, Niesvizky, R. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. New Eng J Med. 2007;357(21):2133–2142.CrossRefGoogle ScholarPubMed
Rajkumar, SV, Hayman, S, Lacy, M. Combination therapy with lenalidomide plus dexamethasone for newly diagnosed myeloma. Blood. 2005;106(13):4050–4053.CrossRefGoogle ScholarPubMed
Rajkumar, SV, Jacobus, S, Callander, N. A randomized trial of lenalidomide plus high dose dexamethasone (RD) versus lenalidomide plus low dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group [abstract]. Blood. 2007;110:74.Google Scholar
Palumbo, A, Falco, P, Benevolo, G. Oral lenalidomide plus melphalan and prednisone for newly diagnosed myeloma [abstract]. J Clin Oncol. 2006;24 Pt 1:18.
Chen, N, Lau, H, Kong, L. Pharmacokinetics of lenalidomide in subjects with varying degrees of renal impairment. J Clin Pharm. 2007;47:1466–1475.CrossRefGoogle Scholar
Richardson, P, Sonneveld, P, Schuster, MW. Bortezomib or high dose dexamethasone for relapsed myeloma. New Engl J Med. 2005;353:2487–2498.CrossRefGoogle Scholar
Richardson, PG, Briemberg, H, Jagannath, S. Frequency, characteristics and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 2006;24(19):3113–3120.CrossRefGoogle ScholarPubMed
Argyrious, A, Iconomou, G, Kalofonos, H. Bortezomib induced peripheral neuropathy in multiple myeloma, a comprehensive review of the literature. Blood. 2008;112:1593–1599.CrossRefGoogle Scholar
Ma, MH, Yang, HH, Parker, K. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res. 2003;9:1136–1144.Google ScholarPubMed
Orlowski, R, Nagler, A, Sonneveld, P. Phase III study of pegylated liposomal doxorubicin and bortezomib compared with bortezomib alone improves time to progression in relapsed or refractory myeloma: results from DOXIL-MY3001. J Clin Oncol. 2007;25(25):3892–3901.CrossRefGoogle ScholarPubMed
San Miguel, J, Schlag, R, Khuageva, N. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. New Engl J Med. 2008;359(9):906–917.CrossRefGoogle ScholarPubMed
Palumbo, A, Bringhen, S, Rossi, D. A prospective randomized phase III study of bortezomib, melphalan, prednisone (VMPT) versus bortezomib, melphalan, and prednisone in elderly newly diagnosed myeloma patients [abstract]. Blood. 2008;112:652.Google Scholar
Mateos, M, Oriol, A, Martinez, J. A prospective multicenter randomized trial of Bortezomib/Melphalan/Prednisone (VMP) versus Bortezomib/Thalidomide Prednisone (VTP) with Bortezomib/Thalidomide (VT) versus Bortezomib Prednisone (VP) in elderly untreated patients with multiple myeloma older than 65 years. Blood. 2009;114:3.Google Scholar
Gay, F.Bringhen, S.Genuardi, M. The weekly infusion of Bortezomib reduces peripheral neuropathy. Blood. 2009; 114:3887.Google Scholar
Child, JA, Morgan, G, Davies, F. High dose chemotherapy with hematopoietic stem cell rescue for multiple myeloma. New Engl J Med. 2003;348(19):1875–1883.CrossRefGoogle ScholarPubMed
Attal, N, Harousseau, J, Stoppa, A. A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français Du Myélome. New Engl J Med. 1996;335(2):91–97.CrossRefGoogle ScholarPubMed
Fietz, T, Rieger, K, Dimeo, F. Stem cell mobilization in multiple myeloma patients: do we need an age adjusted regimen for the elderly?J Clin Apheresis. 2004;19(4):202–207.CrossRefGoogle ScholarPubMed
Morris, C, Siegel, E, Barlogie, B. Mobilization of CD34+ cells in elderly patients with multiple myeloma: influence of age, prior therapy, platelet count, and mobilization regimen. Br J Hematol. 2003;120(2):413–423.CrossRefGoogle ScholarPubMed
Badros, A, Barlogie, B, Siegel, E. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Hematol. 2001;114(3):600–607.CrossRefGoogle ScholarPubMed
Reece, , Bredeson, C, Perez, WS. Autologous stem cell transplantation in multiple myeloma patients <60 years versus >= 60 years. Bone Marrow Transplant. 2003;32(12):1135–1143.CrossRefGoogle Scholar
Kumar, S, Dingli, D, Lacy, M. Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: results from a matched pair analysis. Am J Hematol. 2008;83(8):614–617.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×